HighGravityDataCurrent guidance
18 items
Quest Diagnostics
Guidance from Quest Diagnostics’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 23, 2026
Data checked
Jul 23, 2026
What changed in the Jul 23, 2026 release
Each item compared with the same item in the previous release (Apr 21, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Raised | Net revenues increase: | for FY2026 | “6.8%” – “7.8%” | “8.3%” – “9.2%” | Filing ↗ |
| Raised | Net revenues: | for FY2026 | “$11.78 billion” – “$11.90 billion” | “$11.95 billion” – “$12.05 billion” | Filing ↗ |
| New | Revenues | for FY2026 | — | “between $11.95 billion and $12.05 billion” | Filing ↗ |
| New | Adjusted diluted EPS | for FY2026 | — | “between $11.05 and $11.25” | Filing ↗ |
| Raised | Adjusted diluted EPS: | for FY2026 | “between $10.63 and $10.83” | “$11.05” – “$11.25” | Filing ↗ |
| New | Adjusted effective tax rate | for FY2026 | — | “expected to be consistent with 2025” | Filing ↗ |
| Raised | Cash provided by operations | for FY2026 | “Approximately $1.75 billion” | “Approximately $1.80 billion” | Filing ↗ |
| Reiterated | Capital expenditures | for FY2026 | “Approximately $550 million” | “Approximately $550 million” | Filing ↗ |
Show 6 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Project Nova first wave implementation | for FY2027 | “fall of 2027” | — | Filing ↗ |
| Not restated | Annual revenues for Co-Lab Solutions | for FY2026 | “approximately $1 billion” | — | Filing ↗ |
| Not restated | Adjusted EPS CAGR | for the long term | “7% - 9%” | — | Filing ↗ |
| Not restated | Adjusted EPS* | for the long term | “7% - 9% CAGR” | — | Filing ↗ |
| Not restated | M&A targeted financial criteria - EPS accretion | No period stated | “Accretive to adj EPS in year 1” | — | Filing ↗ |
| Not restated | Physicians channel growth | for the long term | “4% - 5% CAGR” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Annual revenues for Co-Lab Solutions | “approximately $1 billion” | for FY2026 | GAAP-tied | Oct 21, 2025 | 1 | Filing ↗ |
| CoLab revenues | “~$1B in revenues in 2026 including Corewell Health” | for FY2026 | GAAP-tied | Jan 12, 2026 | 1 | Filing ↗ |
| Net revenues increase: | “8.3%” – “9.2%” | for FY2026 | GAAP-tied | Apr 21, 2026 | 2 | Filing ↗ |
| Net revenues: | “$11.95 billion” – “$12.05 billion” | for FY2026 | GAAP-tied | Apr 21, 2026 | 2 | Filing ↗ |
| Revenues | “between $11.95 billion and $12.05 billion” | for FY2026 | GAAP-tied | Jul 23, 2026 | 1 | Filing ↗ |
| Adjusted diluted EPS | “between $11.05 and $11.25” | for FY2026 | Company-defined | Jul 23, 2026 | 1 | Filing ↗ |
| Adjusted diluted EPS: | “$11.05” – “$11.25” | for FY2026 | Company-defined | Apr 21, 2026 | 2 | Filing ↗ |
| Reported diluted EPS | “between $9.58 and $9.78” | for FY2026 | GAAP-tied | Apr 21, 2026 | 1 | Filing ↗ |
| Adjusted effective tax rate | “expected to be consistent with 2025” | for FY2026 | Company-defined | Jul 23, 2026 | 1 | Filing ↗ |
| Capital expenditures | “Approximately $550 million” | for FY2026 | Company-defined | Apr 21, 2026 | 2 | Filing ↗ |
| Cash provided by operations | “Approximately $1.80 billion” | for FY2026 | Company-defined | Apr 21, 2026 | 2 | Filing ↗ |
Next year and medium term
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Adjusted EPS CAGR | “7% - 9%” | for the long term | Company-defined | Jan 12, 2026 | 1 | Filing ↗ |
| Adjusted EPS* | “7% - 9% CAGR” | for the long term | Company-defined | Jan 12, 2026 | 1 | Filing ↗ |
| High-growth areas channel growth | “>20% CAGR” | for the long term | Company-defined | Jan 12, 2026 | 1 | Filing ↗ |
| Hospitals channel growth | “5% - 6% CAGR” | for the long term | Company-defined | Jan 12, 2026 | 1 | Filing ↗ |
| Physicians channel growth | “4% - 5% CAGR” | for the long term | Company-defined | Jan 12, 2026 | 1 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Quarterly dividend | “$3.20 per share annually” | — | Declared action | Jan 30, 2025 | 1 | Filing ↗ |
How one item moved
Cash provided by operations, for FY2025 — every statement across the year, each linked to its filing.
How your Healthcare payers & distributors sector group guides
12 companies in Healthcare payers & distributors. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| UnitedHealth Group | Oct 13, 2026 | 5 changes |
| Cardinal Health | Aug 11, 2026 | 13 changes |
| Cencora | Aug 5, 2026 | 11 changes |
| CVS Health | Aug 5, 2026 | 5 changes |
| McKesson | Aug 5, 2026 | 1 change |
| Labcorp | Jul 30, 2026 | 2 changes |
| The Cigna Group | Jul 30, 2026 | 3 changes |
| Humana | Jul 29, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | FY2024 | Long-term | No period |
|---|---|---|---|---|---|---|
| Advanced diagnostic tests in 5 key clinical areas revenue | — | — | 1 statement | — | — | — |
| Annual revenues for Co-Lab Solutions | — | 1 statement | — | — | — | — |
| CoLab revenues | — | 1 statement | — | — | — | — |
| Net revenues increase: | — | 2 statements | 4 statements | — | — | — |
| Net revenues: | — | 2 statements | — | 1 statement | — | — |
The full record for Quest Diagnostics and its Healthcare payers & distributors peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 23, 2026 | FY2026 Q2 | 0001022079-26-000067 | 8 | Open filing ↗ |
| Apr 21, 2026 | FY2026 Q1 | 0001022079-26-000040 | 7 | Open filing ↗ |
| Jan 12, 2026 | FY2025 Q4 | 0000947871-26-000025 | 25 | Open filing ↗ |
| Oct 21, 2025 | FY2025 Q3 | 0001022079-25-000219 | 7 | Open filing ↗ |
| Jul 22, 2025 | FY2025 Q2 | 0001022079-25-000172 | 6 | Open filing ↗ |
| Apr 22, 2025 | FY2025 Q1 | 0001022079-25-000116 | 4 | Open filing ↗ |
| Jan 30, 2025 | FY2024 Q4 | 0001022079-25-000008 | 5 | Open filing ↗ |
| Oct 22, 2024 | FY2024 Q3 | 0001022079-24-000187 | 5 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error